Videla L., Benejam B., Carmona-Iragui M., Barroeta I., Fernández S., Arranz J., Azzahchi S.E., Altuna M., Padilla C., Valldeneu S., Pegueroles J., Montal V., Aranha M.R., Vaqué-Alcázar L., Iulita M.F., Alcolea D., Bejanin A., Videla S., Blesa R., Lleó A., Fortea J.. Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2023; 19(9)DOI:10.1002/alz.13073. PMID:37038748. IF:13.100(Q1/1D).

Aranha, MR, Iulita M.F., Montal V., Pegueroles J., Bejanin A., Vaqué-Alcázar L., Grothe M.J., Carmona-Iragui M., Videla L., Benejam B., Arranz J., Padilla C., Valldeneu S., Barroeta I., Altuna M., Fernández S., Ribas L., Valle-Tamayo N., Alcolea D., González-Ortiz S., Bargalló N., Zetterberg H., Blennow K., Blesa R., Wisniewski T., Busciglio J., Cuello A.C., Lleó A., Fortea J.. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2023; 19(11)DOI:10.1002/alz.12999. PMID:37021589. IF:13.100(Q1/1D).

Barroeta, I, Videla, L, Carmona-Iragui, M, Fortea, J, Rafii, MS. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70258. PMID:40528298. IF:11.100(Q1/1D).

Sauer, M, Gomes, BF, Shahrouki, P, Lantero-Rodriguez, J, Montoliu-Gaya, L, Camporesi, E, Belbin, O, Alcolea, D, Kumar, A, Sharma, M, Singh, S, Brinkmalm, G, Gobom, J, Carmona-Iragui, M, Schöll, M, Janelidze, S, Deep, G, Blennow, K, Zetterberg, H, Brinkmalm, A, Lleó, A, Fortea, J, Hansson, O, Ashton, NJ, Nilsson, J. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70241. PMID:40522075. IF:11.100(Q1/1D).

Valle-Tamayo, N, Aranha, MR, Pérez-González, R, Serrano-Requena, S, Videla, L, Barroeta, I, Benejam, B, Chiva-Blanch, G, Jimenez, A, Busciglio, J, Wisniewski, T, Do Carmo, S, Alvarez-Sánchez, E, Muñoz, L, Bejanin, A, Belbin, O, Alcolea, D, Carmona-Iragui, M, Lleó, A, Cuello, AC, Fortea, J, Dols-Icardo, O, Iulita, MF. Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum. ALZHEIMERS & DEMENTIA. 2025; 21(4)DOI:10.1002/alz.70137. PMID:40257051. IF:11.100(Q1/1D).

Ivain, P, Baksh, A, Saini, F, Idris, M, Tamayo-Elizalde, M, Wells, J, Benejam, B, Loosli, SV, Sandkühle, K, Wlasich, E, Wagemann, O, Levin, J, Martet, D, Sacco, S, Falquero, S, Clert, M, Rebillat, AS, Khoo, WM, Smith, MA, Beresford-Webb, J, Zaman, S, Carmona-Iragui, M, Videla, L, Fortea, J, Langballe, EM, Medboen, IT, Larsen, FK, Baldimtsi, E, Paradisi, R, Ntailakis, P, Tsolaki, M, Papantoniou, G, Mcglinchey, E, Mccarron, M, Kennelly, S, Strydom, A. Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study. ALZHEIMERS & DEMENTIA. 2025; 21(3)DOI:10.1002/alz.70071. PMID:40145416. IF:11.100(Q1/1D).

Koetsier, J, Cavill, R, Reijnders, R, Harvey, J, Homann, J, Kouhsar, M, Deckers, K, Kohler, S, Eijssen, LMT, van den Hove, DLA, Demuth, I, Düzel, S, Smith, RG, Smith, AR, Burrage, J, Walker, EM, Shireby, G, Hannon, E, Dempster, E, Frayling, T, Mill, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Lill, CM, Bertram, L, Lunnon, K, Pishva, E. Blood-based multivariate methylation risk score for cognitive impairment and dementia. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14061. PMID:39193899. IF:11.100(Q1/1D).

Huber, H, Montoliu-Gaya, L, Brum, WS, Vávra, J, Yakoub, Y, Weninger, H, Braun-Wohlfahrt, LS, Simrén, J, Boada, M, Ruiz, A, Cano, A, Orellana, A, Valero, S, Cañada, L, Tantinya, N, Nogales, AB, Sanz-Cartagena, P, Dittrich, A, Skoog, I, Sander-Long, M, Ballard, C, Richards, M, O'Leary, M, Clemmensen, FK, Wandall, HHD, Altomare, D, Cantoni, V, Stomrud, E, Palmqvist, S, Lleo, A, Alcolea, D, Iragui, MC, Hernandez, AS, Benejam, B, Toro, LV, Singh, A, Denkinger, MN, Simonsen, AH, Kern, S, Corbett, A, Fortea, J, Honigberg, L, Borroni, B, Hansson, O, Morató, X, Blennow, K, Zetterberg, H, Ashton, NJ. A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology. NATURE MEDICINE. 2026; 32(2)DOI:10.1038/s41591-025-04080-0. PMID:41491101. IF:50.000(Q1/1D).